Abstract:Immunocompromised individuals are at risk for developing lymphocryptovirus-associated lymphoproliferative diseases, such as Epstein Barr virus (EBV)-associated B cell lymphomas and post-transplant lymphoproliferative disorder (PTLD). We previously reported development of cynomolgus lymphocryptovirus (CyLCV)-associated PTLD in Mauritian cynomolgus macaques (MCMs) undergoing hematopoietic stem cell transplantation (HSCT), which mirrored EBV-PTLD in transplant patients. Here, we sought to develop a MCM model of lymphocryptovirus-associated lymphoproliferative disease in immunosuppressed MCMs without HSCT. Five simian immunodeficiency virus (SIV)-infected, CD8α+ cell-depleted MCMs received an infusion of autologous B-lymphoblastoid cells transformed with CyLCV, followed by varying degrees of immunosuppression. Four of five infused macaques developed masses coincident with increasing CyLCV plasma viremia, and necropsies confirmed the presence of multicentric lymphomas, which most commonly manifested in lymph nodes, gastrointestinal tract, adrenal glands, and pancreas. Affected tissues harbored neoplastic lymphocytes double-positive for CD20 and CyLCV EBNA2 antigen, large frequencies of proliferating B cells, and high levels of cell-associated CyLCV DNA. In addition, longitudinal 18F-fluorodeoxyglucose positron-emission tomography (18F-FDG PET) of one MCM successfully detected lymphoproliferative disease in the adrenal glands prior to clinical signs of disease. These data demonstrate successful induction of lymphocryptovirus-associated PTLD-like disease in 4 of 5 MCMs, and thus support the use of MCMs as a preclinical NHP model of EBV-associated lymphoproliferative disease that could be employed to test novel diagnostic and therapeutic modalities. Post-transplant lymphoproliferative disorder (PTLD) is a significant transplant-related complication that typically results from uncontrolled proliferation of lymphocryptovirus-infected B cells in the absence of sufficient immune surveillance. We sought to develop a nonhuman primate model of PTLD-like disease by infusing lymphocryptovirus-infected B cells into immunosuppressed Mauritian cynomolgus macaques. This strategy successfully induced lymphocryptovirus-associated lymphoproliferative disease in 4 of 5 studied macaques, who developed LCV+ B cell lymphomas. While further studies are needed to determine the optimal immunosuppressive regimen to universally trigger disease, our findings lay the foundation for a physiologically relevant macaque model of lymphocryptovirus-associated PTLD that can be employed to test new therapies.

Alemtuzumab Used for Induction Therapy in Cynomolgus Model

Lymphocyte depletion and repopulation in peripheral blood and small intestine of cynomolgus monkeys after alemtuzumab treatment.

Campath-1H Depletes Lymphocytes in Blood and Lymphatic Tissues of Cynomolgus Monkeys

The Induction of Dendritic Cells with Ifn-Alpha and Gm-Csf from Bone Marrow Mononuclear Cells from Patients with Chronic Myeloid Leukemia.

Lymphocyte Depletion after Alemtuzumab Induction Disrupts Intestinal Fungal Microbiota in Cynomolgus Monkeys

Efficacy and Safety of Induction Therapy with Alemtuzumab in Kidney Transplantation: A Meta-Analysis

Effect of Alemtuzumab on Intestinal Intraepithelial Lymphocytes and Intestinal Barrier Function in Cynomolgus Model

Reciprocal interaction between intestinal microbiota and mucosal lymphocyte in cynomolgus monkeys after alemtuzumab treatment

A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys

[Establishment of Models for Purging Leukemic Cells from the Grafts in Vitro].

P-029 Prognostic Markers for CAR-T Cell Therapy in Patients with Relapsed/refractory Multiple Myeloma

The Effects of Rhil-11 on Hematopoietic Restoration Following Cyclophosphamide-Induced Thrombocytopenia in Cynomolgus Monkeys

Generation of adenovirus-mediated anti-CD20 antibody and its effect on B-cell deletion in mice and nonhuman primate cynomolgus monkey.

Immunomodulatory Effects of Ox40 Agonists in A Defined Antigen Challenge in Cynomolgus Macaques.

Immunomodulatory Properties of Mesenchymal Stem Cells Combined with Mycophenolate Mofetil Induce T Cell Regulation and Prolong Renal Allografts Survival in Cynomolgus Monkeys

Systemic Immune Response to a CD40-Agonist Antibody in Nonhuman Primates

Tolerance in a concordant nonhuman primate model

Influence of alemtuzumab on the intestinal Paneth cells and microflora in macaques

A model of lymphocryptovirus-associated post-transplant lymphoproliferative disorder in immunosuppressed Mauritian cynomolgus macaques

Species-Specific Involvement of Integrin αIIbβ3 in a Monoclonal Antibody CH12 Triggers Off-Target Thrombocytopenia in Cynomolgus Monkeys.

NCG-MHC-dKO Mice: an Excellent Model for PBMC Reconstitution and Pharmacodynamic Evaluation in the Absence of GvHD